Yazar "Yildiz, S." seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim Yok
    Öğe
    Binding of nucleotides to anti-chloroglyoxime for DNA labeling
    (SPRINGER, 2014) Yildiz, S.; Maltas, E.; Findik, M.; Ozcan, E.
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    DNA labeling of vitamin D receptor gene by using schiff base
    (SPRINGER, 2014) Maltas, E.; Findik, M.; Yildiz, S.; Ozcan, E.
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Effect of quercetin and sinnamic acid on enzyme activity of Galleria mellonella L. (Lepidoptera: Pyrelidae)
    (SPRINGER, 2014) Ozturk, R.; Maltas, E.; Bas, S.; Yildiz, S.
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Evaluation of Antioxidant Activity, Phytochemicals and ESR Analysis of Lavandula Stoechas
    (POLISH ACAD SCIENCES INST PHYSICS, 2015) Ceylan, Y.; Usta, K.; Usta, A.; Maltas, E.; Yildiz, S.
    The antioxidant activity of phytochemicals and of the methanolic extract of Lavandula stoechas was evaluated by beta-carotene-linoleate bleaching, DPPH radical scavenging, ferric reducing/antioxidant power (FRAP). The obtained results were compared with antioxidant activities of synthetic antioxidants, such as BHT and BHA. The highest antioxidant activity of the extract was observed by DPPH radical scavenging assay, which was 84.45 +/- 5.1 % at 1 mg ml(-1). Rutin, rosmarinic acid, and caffeic acid were main phenolics in the extract. The total phenolic content of the methanolic extract of Lavandula stoechas was found to be 105.5 +/- 2.7 mg gallic acid equivalent (GAE). Electron spin resonance (ESR) measurements were also performed on the samples. Free radicals were determined by ESR method. g value was found to be 2.0034 for the Lavandula stoechas; 2.0052 for quercetin.
  • Küçük Resim Yok
    Öğe
    Pantoprazole may improve beta cell function and diabetes mellitus
    (SPRINGER, 2014) Inci, F.; Atmaca, M.; Ozturk, M.; Yildiz, S.; Koceroglu, R.; Sekeroglu, R.; Ipekci, S. H.
    Background Proton pump inhibitors induce hypergastrinemia by suppressing gastric acidity. Gastrin has incretin-like stimulating actions on beta cells. Proton pump inhibitors have been shown to decrease glycosylated hemoglobin. Aim We aimed to observe changes in beta cell function in diabetic and non-diabetic subjects given pantoprazole for an acid-related ailment. Methods Seventy-nine male patients (38 non-diabetic and 41 type-2 diabetic receiving only metformin therapy) were followed for 12 weeks after pantoprazole 40 mg/day was given. Fasting plasma glucose, HbA1c, fasting insulin, Pancreatic B cell function (HOMA-B), proinsulin and c-peptide levels were measured before and after the treatment. Results In non-diabetic patients (n = 38), FPG decreased, whereas c-peptide, log-HOMA-B, increased significantly (p = 0.002, p = 0.03, p = 0.042, respectively) after 12 weeks of pantoprazole administration. In type 2 diabetic patients, FPG, HbA1c and weight decreased, whereas log-HOMA-B, c-peptide and log-proinsulin levels increased significantly after pantoprazole treatment (p = 0.003, p = 0.007, p < 0.001; p < 0.001; p = 0.017, p = 0.05, respectively). After pantoprazole treatment, pancreatic B-cell function was correlated with c-peptide and insulin and inversely with FBG and HbA1c levels in the whole group (r = 0.37, p = 0.001; r = 0.60, p < 0.001, r = -0.29, p = 0.011 and r = -0.28, p = 0.013, respectively). After pantoprazole treatment, HbA1c was correlated with FBG (r = 0.75, p < 0.001) and inversely with only log-HOMA-B level (r = -0.28, p = 0.013). Conclusions Pantoprazole administration seems to correlate with increased beta cell function. Pantoprazole administration improves HbA1c, HOMA-B, c-peptide and proinsulin levels. Since beta cell loss plays a significant role in the pathogenesis of type 2 diabetes, PPI-based therapies may be useful in the treatment of diabetes.